| To get result click here | | | | Beacon Pharmaceuticals Limited (BPL) is a public |
| Subscription Open: June 20, 2010 | | | | limited company, which wasincorporated in |
| Subscription Close: June 24, 2010 | | | | Bangladesh on 12 September 2001 as private |
| For Non-Resident Bangladeshi: June 20, 2010 to | | | | limited companywith the Registrar of Joint Stock |
| July 03, 2010 | | | | Companies and Firms, Dhaka, Bangladeshunder the |
| Reason for IPO To meet the working capital | | | | Companies Act 1994 with a mission to improve |
| requirement. | | | | the quality of humanlife by providing innovating |
| Offer Price Per Share Tk. 10.00 | | | | pharmaceutical products through |
| Face Value Per Share Tk. 10.00 | | | | continuousresearch and development and by |
| Market Lot (Shares) 500 | | | | ensuring stakeholders satisfaction. |
| Pre-IPO Paid-up Capital Tk. 1,900,000,000.00 | | | | The company went into commercial operation on |
| Public Offer (Shares) 30,000,000 | | | | 01 September 2006 by usingits two or three |
| Total Issued Shares (after IPO) 220,000,000 | | | | product lines. The status of the company was |
| Total Paid-up Capital (after IPO) Tk. | | | | covered fromPrivate Limited to Public Limited |
| 2,200,000,000.00 | | | | Company on 25th February 2008. TheAuthorized |
| EPS (as per Prospectus) Tk. 0.31 (as on | | | | Capital of the Company as of 30 April 2009 is |
| 30.06.2009) | | | | Tk.250, 00,00,000divided into 25,00,00,000 |
| NAV Per Share (after revaluation; as per | | | | ordinary shares of Tk. 10.00 each. The paid-up |
| Prospectus) Tk.16.05 (as on 30.06.2009) | | | | sharecapital as of the same date was Tk |
| Website: | | | | 600,000,000 divided into 60,000,000ordinary |
| Nature of Business: | | | | shares of Tk.10.00 each. Subsequently the |
| The Company is engaged in manufacturing | | | | Company issued100,000,000 ordinary shares of |
| andmarketing of pharmaceuticals finished | | | | Tk. 10.00 each amounting to Tk.1,000,000,000.00 |
| FormulationProducts and life saving Intravenous | | | | on 27.09.2009 which consent has been accorded |
| (I.V) Fluids, hitechlyophilized anticancer drugs, | | | | by theSecurities and Exchange Commission on |
| ActivePharmaceuticals Ingredients (APIs), Bio-tech | | | | 04.08.2009; and the Company isgoing to subscribe |
| products& Genetic Engineering products | | | | 30,000,000 ordinary shares of Tk. 10.00 each |
| which it sells in thelocal markets. The Company | | | | totaling Tk.300,000,000, which consent, has been |
| also provides contractmanufacturing and tool | | | | accorded by the Securities andExchange |
| manufacturing services. | | | | Commission on 25.10.2009. Considering the above |
| Beacon Pharmaceuticals Ltd. | | | | events, the paidupcapital before IPO will be stands |
| At a glance | | | | at Tk. 1,900,000,000. |